Mannkind MNKD Commercial Related To Afrezza And Vgo — Cost Of Revenue

Other product segments

Similar metrics at other companies

ABBVTotal Cost of Revenue

$4.22B+5.4%

VCYTCost Of Revenue, Including Amortization

$37.91M+8.4%

AESTotal Cost of Revenue

$2.54B+2.2%

INCYTotal Cost of Revenue

$104.52M+42.8%

CMCTotal Cost of Revenue

$1.74B+13.6%

IONSCommercial — Revenue

$107.81M+41.5%

Questions, answered.

What is Mannkind's commercial related to afrezza and vgo — cost of revenue?

Mannkind (MNKD) reported commercial related to afrezza and vgo — cost of revenue of $7.5M in Q1 2026.

What does commercial related to afrezza and vgo — cost of revenue mean?

This metric represents the direct costs associated with the production, manufacturing, and distribution of the company's primary inhaled therapeutic products. It captures the expenses incurred to bring these specific medical devices and pharmaceutical formulations to market, including raw material costs and manufacturing overhead. Monitoring this figure helps investors evaluate the gross margin efficiency and production scalability of the company's core commercial product portfolio.